Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan
  
Vertex Mobile
Vertex shares are up 35% so far this year, making it one of the sector's top mid-sized performers. • Source: Shutterstock

More from Cell Therapies

More from Therapy Areas